CD39 Activity and Platelet Reactivity in Chronic Lymphocytic Leukemia
Author Information
Author(s): Dianne Pulte, Kim E. Olson, M. Johan Broekman, Naziba Islam, Harold S. Ballard, Richard R. Furman, Ashley E. Olson, Aaron J. Marcus
Primary Institution: Weill Medical College Cornell University
Hypothesis
If CD39 is observed on CLL cells, then patients with CLL may be relatively protected against platelet aggregation and recruitment.
Conclusion
CD39 is expressed and active on CLL cells, with higher enzyme activity in earlier stages of the disease.
Supporting Evidence
- CD39 activity was elevated in stage 0–2 CLL compared to stage 3–4.
- Functional assays demonstrated that ADPase and ATPase activities were much higher in CLL cells than in normal lymphocytes.
- Platelet function tests showed inhibition of platelet activation and recruitment to ADP by CLL cells.
Takeaway
This study found that a protein called CD39 helps prevent blood cells from clumping together in patients with a type of blood cancer called CLL.
Methodology
Lymphocytes were isolated from blood samples, and CD39 activity was measured using radio-TLC assays and FACS analysis.
Limitations
The presence of normal T- or B-lymphocytes in preparations from CLL patients may confound results.
Participant Demographics
{"age":"71.5 y/o (35–95 y/o)","gender":{"male":18,"female":3}}
Statistical Information
P-Value
p < 0.00001
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website